Pfizer/BioNTech target April vaccine trial launch

New York-based global pharmaceutical giant Pfizer Inc is teaming up with BioNTech to rapidly develop the Mainz, Germany-based firm’s BNT162, a messenger RNA-based potential vaccine for COVID-19. The compound is expected to enter clinical testing by the end of April 2020, according to the two companies. If successful, it would prevent contraction of COVID-19 in … Continue reading Pfizer/BioNTech target April vaccine trial launch